The ε4 Allele of the APOE gene is associated with more severe peripheral neuropathy in type 2 diabetic patients

Angiology

Volumn 64, Issue 6, 2013, Pages 451-455

  Monastiriotis, C ^a   Papanas, N ^a   Trypsianis, G ^a   Karanikola, K ^a   Veletza, S ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

apolipoprotein E; diabetes mellitus; diabetic neuropathy; genes; polymorphisms

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HEMOGLOBIN A1C;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL EXAMINATION; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; RISK FACTOR;

APOLIPOPROTEIN E; DIABETES MELLITUS; DIABETIC NEUROPATHY; GENES; POLYMORPHISMS;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISABILITY EVALUATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84881250308     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712453645     Document Type: Article

References (48)

1. Shaw JE, Zimmet PZ, Gries FA, Ziegler D Textbook of Diabetic Neuropathy. C Gries Ziegler Low, ed. New York, NY: Thieme Verlag ; 2003: 64-79.
2. Young MJ, Boulton AJ, Macleod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993 ; 36 (2). 150-154
3. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008 ; 24 (suppl 1). S3 - S6
4. Edmonds ME. The diabetic foot, 2003. Diabetes Metal Res Rev. 2004 ; 20 (suppl 1). S9 - S12
5. Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs?. Diabetes Care. 2009 ; 32 (suppl 2). S414 - S419
6. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 ; 33 (10). 2285-2293
7. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999 ; 22 (9). 1479-1486
8. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008 ; 10 (2). 99-108
9. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early. Nat Rev Endocrinol. 2011 ; 7 (11). 682-690
10. Sivenius K, Pihlajamaki J, Partanen J, Niskanen L, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care. 2004 ; 27 (8). 2021-2026
11. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001 ; 18 (12). 945-959
12. Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia. 1997 ; 40 (5). 506-511
13. Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Christakidis D, Maltezos M. An insertion/deletion polymorphism in the Alpha2B adrenoreceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007 ; 115 (5). 327-330
14. Anjaneyulu M, Berent-Spillson A, Russel JW. Metabotropic glutamate receptors (mGluRs) and diabetic neuropathy. Curr Drug Targets. 2008 ; 9 (1). 85-93
15. Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV I and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol. 2007 ; 7: 11
16. Voron'ko OE, Lakunina NIu, Strokov IA, Lavrova IN, Nosikov VV.. [Association of polymorphic markers of the lipid metabolism genes with diabetic neuropathy in type 1 diabetes mellitus.]. Mol Biol (Mosk). 2005 ; 39 (2). 230-234
17. Mahley RW. Apolipoprotein E cholesterol transport protein with expanding role in cell biology. Science. 1988 ; 240 (4852). 622-630
18. Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res. 1987 ; 28 (4). 371-380
19. Hixxson JE Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res. 1990 ; 31 (3). 545-548
20. Bedlack RS, Strittmatter WJ, Morgenlander JC. Apolipoprotein E and neuromuscular disease: a critical review of literature. Arch Neurol. 2000 ; 57 (11). 1561-1565
21. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 ; 14 (1). 55-61
22. Boyles J, Pitas R, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985 ; 76 (4). 1501-1513
23. Skene J, Shooter E. Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci U S A. 1983 ; 80 (13). 4169-4173
24. Gelman BB, Rifai N, Goodrum JF, Bouldin TW, Krigman MR. Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination. J Neuropathol Exp Neurol. 1987 ; 46 (6). 644-652
25. Tsuzuki S, Murano T, Watanabe H, Itoh Y, Miyashita Y, Shirai K.. [The examination of apoE phenotypes in diabetic patients with peripheral neuropathy.]. Rinsho Byori. 1998 ; 46 (8). 829-833
26. Bedlack RS, Edelman D, Gibbs JW, et al. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology. 2003 ; 60 (6). 1022-1024
27. Zhou Z, Hoke A, Cornblath DR, Griffin JW, Polydefkis M. APOE epsilon4 is not a succeptibility gene in idiopathic or diabetic sensory neuropathy. Neurology. 2005 ; 64 (1). 139-141
28. Paisley AN, Abbott CA, van Schie CH, Boulton AJ. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med. 2002 ; 19 (5). 400-405
29. Papanas N, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Maltezos E. A comparison of the new indicator test for sudomotor function (Neuropad®) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2008 ; 116 (2). 135-138
30. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002 ; 19 (5). 377-384
31. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 ; 16 (3). 1215
32. Reymer PW, Groenemeyer BE, van de Burg R, Kastelein JJ. Apolipoprotein E genotyping on agarose gels. Clin Chem. 1995 ; 41 (7). 1046-1047
33. Karpouzis A, Caridha R, Tripsianis G, Michailidis C, Martinis G, Veletza SV.. Apolipoprotein E gene polymorphism in psoriasis. Arch Dermatol Res. 2009 ; 301 (6). 405-410
34. Sklavounou E, Economou-Petersen E, Karadima G, et al. Apolipoprotein E polymorphism in the Greek population. Clin Genet. 1997 ; 52 (4). 216-218
35. Kolovou G, Daskalova D, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology. 2003 ; 54 (1). 59-71
36. Kolovou GD, Anagnostopoulou KK, Mikhailidis DP, et al. Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology. 2005 ; 56 (6). 663-670
37. Pitas R, Boyles J, Lee S, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987 ; 917 (1). 148-161
38. Smith JD, Miyata M, Poulin SE, Neveux LM, Craig WY. The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res. 1998 ; 28 (2). 116-121
39. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 2008 ; 52 (1). 131-145
40. Miyata M, Smith JD. Apolipoprotein E allele specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996 ; 14 (1). 55-61
41. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993 ; 90 (5). 1977-1981
42. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci U S A. 1995 ; 92 (11). 4725-4727
43. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science. 1993 ; 261 (5123). 921-923
44. Corder E, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nat Genet. 1994 ; 7 (2). 180-184
45. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996 ; 16 (10). 1250-1255
46. Papanas N, Katsiki N, Papatheodorou K, et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology. 2011 ; 62 (4). 291-295
47. Papanas N, Maltezos E. Cilostazol in diabetic neuropathy: premature farewell or new beginning?. Angiology. 2011 ; 62 (8). 605-608
48. Papanas N. Maltezos E. α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology. 2012 ; 63 (2). 81-83